Cambridge Investment Research Advisors Inc. Raises Stock Holdings in AbbVie Inc. $ABBV

Cambridge Investment Research Advisors Inc. grew its stake in AbbVie Inc. (NYSE:ABBV) by 1.8% during the 4th quarter, Holdings Channel reports. The fund owned 545,217 shares of the company’s stock after acquiring an additional 9,761 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in AbbVie were worth $124,577,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Chelsea Counsel Co. purchased a new stake in shares of AbbVie in the third quarter valued at $26,000. Westend Capital Management LLC purchased a new stake in shares of AbbVie in the fourth quarter valued at $29,000. Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie in the third quarter valued at $31,000. Legacy Wealth Managment LLC ID lifted its position in shares of AbbVie by 115.9% in the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after acquiring an additional 73 shares in the last quarter. Finally, WestEnd Advisors LLC lifted its position in shares of AbbVie by 160.4% in the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after acquiring an additional 85 shares in the last quarter. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Q1 results were supported by strong sales of Skyrizi and Rinvoq, which helped offset ongoing Humira declines and boosted the company’s 2026 guidance. Article: How Important Are Skyrizi and Rinvoq to AbbVie’s Q1 Results?
• Positive Sentiment: Analysts have turned more optimistic on AbbVie’s earnings power, with Erste Group raising FY2027 EPS estimates and the company’s long-term pipeline still viewed favorably.
• Positive Sentiment: Recent commentary highlighted AbbVie as a potentially better growth story than AstraZeneca because of its valuation, dividend profile, and pipeline strength. Article: Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on ABBV shares. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research report on Sunday. Morgan Stanley upped their price objective on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a research report on Thursday, April 30th. Canaccord Genuity Group upped their price objective on AbbVie from $262.00 to $265.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Evercore set a $235.00 price objective on AbbVie in a research report on Friday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $240.00 target price on shares of AbbVie in a research report on Thursday, April 30th. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.43.

AbbVie Trading Down 0.1%

NYSE ABBV opened at $210.54 on Friday. The business’s 50-day moving average price is $210.27 and its 200 day moving average price is $220.10. AbbVie Inc. has a twelve month low of $180.25 and a twelve month high of $244.81. The company has a market capitalization of $371.98 billion, a PE ratio of 103.71, a price-to-earnings-growth ratio of 0.73 and a beta of 0.32.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same period in the prior year, the business posted $2.46 earnings per share. The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. Equities analysts predict that AbbVie Inc. will post 14.3 EPS for the current year.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, May 15th. Investors of record on Wednesday, April 15th were given a dividend of $1.73 per share. The ex-dividend date was Wednesday, April 15th. This represents a $6.92 annualized dividend and a yield of 3.3%. AbbVie’s dividend payout ratio is 340.89%.

Insider Transactions at AbbVie

In other news, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president directly owned 38,137 shares in the company, valued at $8,771,510. This trade represents a 36.98% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 0.06% of the company’s stock.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.